Systemic Treatment of Patients Who Have Colorectal Cancer and Inflammatory Bowel Disease

Gastroenterology Clinics of North America

Volumn 35, Issue 3, 2006, Pages 713-727

  Goessling, Wolfram ^a,c,d   Mayer, Robert J ^a,b,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CORTICOSTEROID; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; LOPERAMIDE; MERCAPTOPURINE; OXALIPLATIN; PANITUMUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANATOMY; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HYDROLYSIS; DRUG POTENTIATION; DRUG USE; ENTERITIS; EXPERIENCE; GASTROENTEROLOGY; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; INTESTINE INJURY; INTESTINE PERFORATION; MEDICAL SPECIALIST; MULTIMODALITY CANCER THERAPY; NECROTIZING ENTEROCOLITIS; NEUTROPENIA; NONHUMAN; ONCOLOGY; PATIENT CARE; PROTEINURIA; RARE DISEASE; REVIEW; SENSORY NEUROPATHY; SEPSIS; STOMATITIS; SYMPTOMATOLOGY; ULCERATIVE COLITIS; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 33748112605     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2006.07.006     Document Type: Review

References (90)

1. Bernstein C.N., Blanchard J.F., Kliewer E., et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91 4 (2001) 854-862
2. Jess T., Loftus Jr. E.V., Velayos F.S., et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology 130 4 (2006) 1039-1046
3. Jess T., Winther K.V., Munkholm P., et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 19 3 (2004) 287-293
4. Persson P.G., Karlen P., Bernell O., et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 107 6 (1994) 1675-1679
5. Gillen C.D., Walmsley R.S., Prior P., et al. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35 11 (1994) 1590-1592
6. Canavan C., Abrams K.R., and Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 23 8 (2006) 1097-1104
7. Greenstein A.J., Sachar D.B., Smith H., et al. A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer 48 12 (1981) 2742-2745
8. Connell W.R., Sheffield J.P., Kamm M.A., et al. Lower gastrointestinal malignancy in Crohn's disease. Gut 35 3 (1994) 347-352
9. Prezyna A.P., and Kalyanaraman U. Bowen's carcinoma in vulvovaginal Crohn's disease (regional enterocolitis): report of first case. Am J Obstet Gynecol 128 8 (1977) 914-916
10. Askling J., Brandt L., Lapidus A., et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54 5 (2005) 617-622
11. Caspi O., Polliack A., Klar R., et al. The association of inflammatory bowel disease and leukemia-coincidence or not?. Leuk Lymphoma 17 3-4 (1995) 255-262
12. Farrell R.J., Ang Y., Kileen P., et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47 4 (2000) 514-519
13. Kwon J.H., and Farrell R.J. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 56 1 (2005) 169-178
14. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 8 (2005) 1121-1125
15. Greenstein A.J., Gennuso R., Sachar D.B., et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 56 12 (1985) 2914-2921
16. Raderer M., Puspok A., Birkner T., et al. Primary gastric mantle cell lymphoma in a patient with long standing history of Crohn's disease. Leuk Lymphoma 45 7 (2004) 1459-1462
17. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
18. Jess T., Gamborg M., Matzen P., et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100 12 (2005) 2724-2729
19. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126 2 (2004) 451-459
20. Jess T., Loftus Jr. E.V., Harmsen W.S., et al. Survival and cause-specific mortality in patients with inflammatory bowel disease: a long-term outcome study in Olmsted County, Minnesota, 1940-2004. Gut (2006) in press
21. Delaunoit T., Limburg P.J., Goldberg R.M., et al. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 4 3 (2006) 335-342
22. Itzkowitz S.H., and Present D.H. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11 3 (2005) 314-321
23. Choi P.M., Nugent F.W., Schoetz Jr. D.J., et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 105 2 (1993) 418-424
24. Karlen P., Kornfeld D., Brostrom O., et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population-based case control study. Gut 42 5 (1998) 711-714
25. Lindberg J., Stenling R., Palmqvist R., et al. Efficiency of colorectal cancer surveillance in patients with ulcerative colitis: 26 years' experience in a patient cohort from a defined population area. Scand J Gastroenterol 40 9 (2005) 1076-1080
26. Collins P., Mpofu C., Watson A., et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2 (2006) CD000279
27. Greenstein A.J. Cancer in inflammatory bowel disease. Mt Sinai J Med 67 3 (2000) 227-240
28. Chawla A., Judge T.A., and Lichtenstein G.R. Evaluation of polypoid lesions in inflammatory bowel disease. Gastrointest Endosc Clin N Am 12 3 (2002) 525-534
29. Itzkowitz S.H., and Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126 6 (2004) 1634-1648
30. Yamazaki Y., Ribeiro M.B., Sachar D.B., et al. Malignant colorectal strictures in Crohn's disease. Am J Gastroenterol 86 7 (1991) 882-885
31. Kiesslich R., Hoffman A., and Neurath M.F. Colonoscopy, tumors, and inflammatory bowel disease - new diagnostic methods. Endoscopy 38 1 (2006) 5-10
32. Meyerhardt J.A., and Mayer R.J. Systemic therapy for colorectal cancer. N Engl J Med 352 5 (2005) 476-487
33. Tiersten A., and Saltz L.B. Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy. J Clin Oncol 14 7 (1996) 2043-2046
34. Chau I., Norman A.R., Cunningham D., et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16 4 (2005) 549-557
35. Andre T., Colin P., Louvet C., et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21 15 (2003) 2896-2903
36. Haller D.G., Catalano P.J., Macdonald J.S., et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23 34 (2005) 8671-8678
37. Erlichman C., Fine S., Wong A., et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6 3 (1988) 469-475
38. Poon M.A., O'Connell M.J., Moertel C.G., et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7 10 (1989) 1407-1418
39. Cocconi G., Cunningham D., Van Cutsem E., et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 16 9 (1998) 2943-2952
40. Petrelli N., Douglass Jr. H.O., Herrera L., et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7 10 (1989) 1419-1426
41. Buroker T.R., O'Connell M.J., Wieand H.S., et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12 1 (1994) 14-20
42. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16 11 (1998) 3537-3541
43. Wolpin B.M., Meyerhardt J.A., Mamon H.J., et al. Adjuvant therapy in colorectal cancer. CA Cancer J Clin (2006) in press
44. Fata F., Ron I.G., Kemeny N., et al. 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 86 7 (1999) 1129-1134
45. Van Cutsem E., Twelves C., Cassidy J., et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19 21 (2001) 4097-4106
46. Hoff P.M., Ansari R., Batist G., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19 8 (2001) 2282-2292
47. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 26 (2005) 2696-2704
48. Abigerges D., Armand J.P., Chabot G.G., et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86 6 (1994) 446-449
49. Ando M., Hasegawa Y., and Ando Y. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Invest New Drugs 23 6 (2005) 539-545
50. Mehra R., Murren J., Chung G., et al. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism. Clin Colorectal Cancer 5 1 (2005) 61-64
51. Innocenti F., Undevia S.D., Iyer L., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 8 (2004) 1382-1388
52. Massacesi C., Terrazzino S., Marcucci F., et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106 5 (2006) 1007-1016
53. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 13 (2000) 905-914
54. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 9209 (2000) 1041-1047
55. Kuehr T., Ruff P., Rapoport B.L., et al. Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer 4 (2004) 36
56. Blanke C.D., Haller D.G., Benson A.B., et al. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann Oncol 12 11 (2001) 1575-1580
57. Rougier P., Bugat R., Douillard J.Y., et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15 1 (1997) 251-260
58. Sargent D.J., Niedzwiecki D., O'Connell M.J., et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345 2 (2001) 144-145
59. Lehky T.J., Leonard G.D., Wilson R.H., et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29 3 (2004) 387-392
60. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 16 (2000) 2938-2947
61. Kemeny N., Garay C.A., Gurtler J., et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22 23 (2004) 4753-4761
62. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
63. Wolmark N., Wieand H.S., Keubler J.P., et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of the NSABP protocol C-07. [abstract]. J Clin Oncol 23 16S (2005) 246s
64. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 11 (2005) 2445-2459
65. Roskoski Jr. R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319 1 (2004) 1-11
66. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
67. Laux I., Jain A., Singh S., et al. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 94 1 (2006) 85-92
68. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 22 (2005) 5235-5246
69. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 7 (2004) 1201-1208
70. Folprecht G., Lutz M.P., Schoffski P., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17 3 (2006) 450-456
71. Malecka-Panas E., Kordek R., Biernat W., et al. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology 44 14 (1997) 435-440
72. Bernal N.P., Stehr W., Coyle R., et al. Epidermal growth factor receptor signaling regulates Bax and Bcl-w expression and apoptotic responses during intestinal adaptation in mice. Gastroenterology 130 2 (2006) 412-423
73. Egger B., Buchler M.W., Lakshmanan J., et al. Mice harboring a defective epidermal growth factor receptor (waved-2) have an increased susceptibility to acute dextran sulfate-induced colitis. Scand J Gastroenterol 35 11 (2000) 1181-1187
74. Abud H.E., Watson N., and Heath J.K. Growth of intestinal epithelium in organ culture is dependent on EGF signalling. Exp Cell Res 303 2 (2005) 252-262
75. Clark J.A., Lane R.H., Maclennan N.K., et al. Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 288 4 (2005) G755-G762
76. Procaccino F., Reinshagen M., Hoffmann P., et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 107 1 (1994) 12-17
77. McCole D.F., Rogler G., Varki N., et al. Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis. Gastroenterology 129 2 (2005) 591-608
78. FitzGerald A.J., Pu M., Marchbank T., et al. Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides 25 5 (2004) 793-801
79. Chinery R., and Playford R.J. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci (Lond) 88 4 (1995) 401-403
80. Dvorak B. Epidermal growth factor and necrotizing enterocolitis. Clin Perinatol 31 1 (2004) 183-192
81. Lordick F., Geinitz H., Theisen J., et al. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 64 5 (2006) 1295-1298
82. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 3 (2005) 173-180
83. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 15 (2005) 3502-3508
84. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 16 (2005) 3706-3712
85. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
86. Giantonio B.J., Catalano P.J., and Meropol N.J. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. [abstract]. J Clin Oncol 23 16S (2005) 1s
87. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 16 (2005) 3697-3705
88. Zhao J., Huang L., Belmar N., et al. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 10 8 (2004) 2851-2859
89. Bourreille A., Doubremelle M., de la Bletiere D.R., et al. RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease. Scand J Gastroenterol 38 5 (2003) 526-532
90. Travis S., Yap L.M., Hawkey C., et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 11 8 (2005) 713-719